CLEVELAND, Ohio (Ivanhoe Newswire) - After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once, 20 to 30 percent will show signs of ...

EDAP management highlighted what it sees as a growing global opportunity for therapeutic ultrasound in urology, emphasizing ...

EDAP TMS (EDAP) announced the publication of the full results from the HIFI study in the prestigious, peer-reviewed journal, European Urology, which has the highest impact factor amongst scientific ...

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S ...

LYON, France, March 21, 2023 -- EDAP TMS SA (EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced a recent presentation of positive results from a large, ...

HIFI Study is the largest (N = 3,328) prospective, comparative, multi-center clinical study ever conducted comparing prostate cancer treatments Positive study results are expected to drive further ...

Focal therapy, including HIFU, targets only cancerous prostate areas, preserving organ function and minimizing side effects like erectile dysfunction and urinary incontinence. HIFU is suitable for ...